Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: A Danish, population-based, 6-year follow-up study

被引:28
作者
Lohse, N
Kronborg, G
Gerstoft, J
Larsen, CS
Pedersen, G
Pedersen, C
Sorensen, HT
Obel, N
机构
[1] Odense Univ Hosp, Dept Infect Dis, DK-5000 Odense, Denmark
[2] Univ So Denmark, Odense, Denmark
[3] Hvidovre Univ Hosp, Dept Infect Dis, DK-2650 Hvidovre, Denmark
[4] Rigshosp, Dept Infect Dis, DK-2100 Copenhagen, Denmark
[5] Skejby Univ Hosp, Dept Infect Dis, Aarhus, Denmark
[6] Aarhus Univ Hosp, Dept Clin Epidemiol, DK-8000 Aarhus, Denmark
[7] Aalborg Univ Hosp, Dept Infect Dis, Aalborg, Denmark
[8] Boston Univ, Dept Epidemiol, Boston, MA 02215 USA
关键词
D O I
10.1086/498515
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Our objective was to examine whether virological control during the first 6-18 months after HAART initiation is a predictor for viral suppression, CD4(+) cell count increase, and mortality in human immunodeficiency virus (HIV)-infected patients 18-90 months after initiation of highly active antiretroviral therapy (HAART). Methods. We conducted a population-based observational cohort study in Denmark. Patients were divided into 3 groups, according to the proportion of time each patient had a detectable HIV RNA load (i.e., >= 400 copies/mL) during the 6-18 months after HAART initiation: 0% of the time interval (group 1), 1%-99% of the time interval (group 2), and 100% of the time interval (group 3). The proportion of patients with undetectable HIV RNA, CD4(+) cell count changes, and mortality were examined by logistic, linear, and Cox regression analyses, respectively. We constructed cumulative mortality curves. Results. We observed 2046 patients, for a total of 8898 person-years of follow-up that started at 18 months after HAART initiation. Mean CD4(+) cell count increase rates during 72 months of follow-up were as follows: group 1, 3.3 x 10(6) cells/L per month (95% CI, 2.5-3.3 x 10(6) cells/L); and group 3, 2.6 x 10(6) (95% CI, 2.0-3.3 x 10(6) cells/L). Survival at 72 months were as follows: group 1, 92.7% (95% CI, 90.5%-94.4%); group 2, 85.6% (95% CI, 82.1%-88.5%); and group 3, 76.1% (95% CI, 70.6%-80.7%). At 72 months, 96% of group 1, 83% of group 2, and 57% of group 3 had an HIV RNA load of <400 copies/mL (P<.01). Treatment interruption before baseline was a predictor of mortality in group (adjusted rate ratio, 2.94; 95% CI, 1.75-4.92]). Conclusions. Viral suppression during the first 6-18 months after HAART initiation predicts viral suppression, CD4(+) cell count progression, and survival at 72 months.
引用
收藏
页码:136 / 144
页数:9
相关论文
共 31 条
[1]   The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy [J].
Anastos, K ;
Barrón, Y ;
Cohen, MH ;
Greenblatt, RM ;
Minkoff, H ;
Levine, A ;
Young, M ;
Gange, SJ .
ANNALS OF INTERNAL MEDICINE, 2004, 140 (04) :256-264
[2]   Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults [J].
Bartlett, JA ;
DeMasi, R ;
Quinn, J ;
Moxham, C ;
Rousseau, F .
AIDS, 2001, 15 (11) :1369-1377
[3]  
Chene G, 2003, LANCET, V362, P679, DOI 10.1016/S0140-6736(03)14229-8
[4]   Guidelines for using antiretroviral agents among HIV-infected adults and adolescents - The panel on clinical practices for treatment of HIV [J].
Dybul, M ;
Fauci, AS ;
Bartlett, JG ;
Kaplan, JE ;
Pau, AK .
ANNALS OF INTERNAL MEDICINE, 2002, 137 (05) :381-433
[5]   The natural history and clinical significance of intermittent viraemia in patients with initial viral suppression to &lt; 400 copies/ml [J].
Easterbrook, PJ ;
Ives, N ;
Waters, A ;
Mullen, J ;
O'Shea, S ;
Peters, B ;
Gazzard, BG .
AIDS, 2002, 16 (11) :1521-1527
[6]   Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy:: a collaborative analysis of prospective studies [J].
Egger, M ;
May, M ;
Chêne, G ;
Phillips, AN ;
Ledergerber, B ;
Dabis, F ;
Costagliola, D ;
Monforte, AD ;
de Wolf, F ;
Reiss, P ;
Lundgren, JD ;
Justice, AC ;
Staszewski, S ;
Leport, C ;
Hogg, RS ;
Sabin, CA ;
Gill, MJ ;
Salzberger, B ;
Sterne, JAC .
LANCET, 2002, 360 (9327) :119-129
[7]  
*EUR AIDS CLIN SOC, 2003, AIDS S2, V17, pS3
[8]   MODELING AND VARIABLE SELECTION IN EPIDEMIOLOGIC ANALYSIS [J].
GREENLAND, S .
AMERICAN JOURNAL OF PUBLIC HEALTH, 1989, 79 (03) :340-349
[9]   Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine [J].
Gulick, RM ;
Meibohm, A ;
Havlir, D ;
Eron, JJ ;
Mosley, A ;
Chodakewitz, JA ;
Isaacs, R ;
Gonzalez, C ;
McMahon, D ;
Richman, DD ;
Robertson, M ;
Mellors, JW .
AIDS, 2003, 17 (16) :2345-2349
[10]   Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection [J].
Gulick, RM ;
Ribaudo, HJ ;
Shikuma, CM ;
Lustgarten, S ;
Squires, KE ;
Meyer, WA ;
Acosta, EP ;
Schackman, BR ;
Pilcher, CD ;
Murphy, RL ;
Maher, WE ;
Witt, MD ;
Reichman, RC ;
Snyder, S ;
Klingman, KL ;
Kuritzkes, DR .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (18) :1850-1861